Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 3/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 4/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 2/20 | 0.33 |
| ▸ | PRKACG | P22612 | 2/20 | 0.33 |
| ▸ | PRKACB | P22694 | 2/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491122 | 0.91 | JAK3 (0.40) | JAK3CNR1CNR2KITSIRT2 | |
| SCHEMBL31374403 | 0.84 | JAK3 (0.58) | JAK3KITAKT2LIMK2AKT1 | |
| SCHEMBL390884 | 0.84 | JAK3 (0.58) | JAK3KITAKT2LIMK2AKT1 | |
| SCHEMBL3491159 | 0.83 | SIRT2 (0.40) | JAK3CNR1CNR2KITSIRT2 | |
| SCHEMBL3491986 | 0.82 | PDGFRB (0.47) | KITAKT2LIMK2AKT1ROCK2 | |
| SCHEMBL391942 | 0.80 | AKT1 (0.46) | JAK3LIMK2AKT1ROCK2AURKA | |
| SCHEMBL11946593 | 0.79 | CNR1 (0.37) | JAK3CNR1CNR2KITSIRT2 | |
| SCHEMBL3491075 | 0.79 | CNR1 (0.36) | JAK3CNR1CNR2KITAKT2 | |
| SCHEMBL3490306 | 0.78 | CNR1 (0.36) | CNR1CNR2KITLIMK2AKT1 | |
| SCHEMBL3490615 | 0.78 | CNR1 (0.37) | CNR1CNR2KITLIMK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2125805-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | JAK3 225/4885CNR1 523/4885CNR2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.